March 22 Quick Takes: Ionis falls as Genentech halts Huntington’s trial; plus Pfizer, Evotec-Takeda, Everest, BioCryst and Odonate
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) has discontinued its Phase III GENERATION HD1 study of tominersen (RG6042) in manifest Huntington’s disease based on a recommendation by its IDMC following a review of the program’s benefit-risk profile. Genentech, which has rights to the antisense molecule targeting huntingtin protein from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), also paused dosing in the open-label GEN-EXTEND extension study. Ionis was off 20% to $44.50 in after-hours trading.
Positive interim Phase III data for Tecentriq in NSCLC
Genentech said the Phase III IMpower010 study of Tecentriq atezolizumab vs. best supportive care met its primary endpoint of disease-free survival at the interim analysis in patients with Stage II-IIIA non-small cell lung cancer (NSCLC). ...